{Reference Type}: Journal Article
{Title}: Robot-Assisted Retroperitoneal Lymphadenectomy in Testicular Cancer Treatment: A Systematic Review.
{Author}: Tselos A;Moris D;Tsilimigras DI;Fragkiadis E;Mpaili E;Sakarellos P;Vailas M;Shah KN;Papalampros A;
{Journal}: J Laparoendosc Adv Surg Tech A
{Volume}: 28
{Issue}: 6
{Year}: Jun 2018
{Factor}: 1.766
{DOI}: 10.1089/lap.2017.0672
{Abstract}: <B>BACKGROUND: </B>Retroperitoneal lymph node dissection (RPLND) in testicular cancer is a documented treatment along with active surveillance and chemotherapy. This study aims to summarize the current evidence on the use of Robot-assisted RPLND (RARPLND) in comparison with the laparoscopic and open approach.<BR><B>METHODS: </B>A search was conducted in the existing literature focusing on reports with outcomes of RARPLND for stage I-IIB testicular tumor.<BR><B>RESULTS: </B>Eleven studies complied with the inclusion criteria, including 116 patients. The average follow-up of 21.2 months showed no retroperitoneal recurrence. The median lymph node yield was 22.3 and the overall positive rate was 26%. Complications were encountered in 8% of the patients. The robotic approach showed similar results to the laparoscopic approach and outperformed the open procedure in perioperative parameters.<BR><B>CONCLUSIONS: </B>Relapse-free survival, nodal yield, and complication rates during RARPLND for clinical stage I-IIB are acceptable. Further studies are required to establish these findings and determine benefit from the use of robotic approach.